Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
point decrease » point increase (Expand Search)
based case » base case (Expand Search), based cancer (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
point decrease » point increase (Expand Search)
based case » base case (Expand Search), based cancer (Expand Search)
-
121
-
122
Summary of the earliest time point for significant WD-induced changes in NASH-associated markers.
Published 2023“…The figure illustrates the earliest time point for a significant change in the marker abundance and whether the marker <b>Increased</b> or <b>Decreased</b> in response to the WD. …”
-
123
-
124
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
125
-
126
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
127
-
128
-
129
-
130
-
131
-
132
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
133
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
134
-
135
-
136
-
137
-
138
-
139
-
140